Norvir

(Ritonavir)

ApprovedSmall molecule

Ritonavir is used to treat HIV infection by slowing the virus's ability to multiply in the body. It's often combined with other HIV medications to help keep the infection under control.[2] Norvir is currently approved and in use across 22 indications[4].[1]

Norvir is one of 518 small molecule programs targeting AIDS. It is currently in Approved.

Indications

319

Total Trials

Active Trials

517

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

AIDSApproved

Anal NeoplasmApproved

Middle East Respiratory SyndromeApproved

HIV InfectionNot yet recruiting

MetastasisApproved

Viral DiseaseActive, not recruiting

Erectile DysfunctionApproved

ToxicityActive, not recruiting

LymphomaActive, not recruiting

Long COVID-19Approved

AIDSApproved

Approved

Anal NeoplasmApproved

Approved

Middle East Respiratory SyndromeApproved

Approved

HIV InfectionApproved

Not yet recruiting

MetastasisApproved

Approved

Viral DiseaseApproved

Active, not recruiting

Erectile DysfunctionApproved

Approved

ToxicityApproved

Active, not recruiting

LymphomaPreclinical

Active, not recruiting

Long COVID-19Approved

Approved

Showing 10 of 22 indications

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

Norvir

AbbVie

Approved

1 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interaction17 trials

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00039975·32 enrolled

The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000898·18 enrolled

Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000906·12 enrolled

Show 14 more trials

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

Completed·RR-Pharm·Phase 1·NCT03537404·36 enrolled

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01519336·40 enrolled

Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02256774·51 enrolled

A Study on the Interaction Between Danoprevir/Ritonavir and Methadone

Completed· Roche logo

Roche·Phase 1·NCT01389544·18 enrolled

The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02251119·24 enrolled

A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01514968·18 enrolled

Drug-Drug Interaction Study: ASP2151 and Ritonavir

Completed·MMaruho Europe Limited·Phase 1·NCT02223351·48 enrolled

Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00936793·53 enrolled

Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253901·33 enrolled

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 1·NCT01323257·49 enrolled

Drug-drug Interaction (DDI) Rifabutin

Completed· GSK logo

GSK·Phase 1·NCT02138084·102 enrolled

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000941·56 enrolled

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

Completed· GSK logo

GSK·Phase 1·NCT00867152·17 enrolled

A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat

Completed·RRadboud University Medical Center·Phase 1·NCT02565888·16 enrolled

Effectiveness12 trials

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001075·55 enrolled

Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00004584

Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

Terminated·AAgouron Pharmaceuticals·N/A·NCT00006326·60 enrolled

Show 9 more trials

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002451·8 enrolled

Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002361·30 enrolled

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

Unknown status· GSK logo

GSK·Phase 4·NCT00005017·300 enrolled

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000914·800 enrolled

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002241·80 enrolled

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001087·300 enrolled

The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00005118·100 enrolled

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001108·6 enrolled

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001091·200 enrolled

Treatment11 trials

A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00006152·42 enrolled

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

Completed· Roche logo

Roche·Phase 3·NCT00002178·375 enrolled

Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment

Active, not recruiting·NNova Scotia Health Authority·Phase 4·NCT02460133·44 enrolled

Show 8 more trials

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

Completed·TTibotec, Inc·Phase 4·NCT00757783·68 enrolled

Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000940·121 enrolled

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients

Completed·TTibotec, Inc·Phase 2·NCT01199939·54 enrolled

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01138605·46 enrolled

Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment

Unknown status·—·N/A·NCT00006591

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00056641·328 enrolled

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00051831·19 enrolled

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00530920·85 enrolled

Tics11 trials

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 1·NCT03288636·18 enrolled

Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253914·100 enrolled

Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253797

Show 8 more trials

The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT01148004·25 enrolled

Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02159352·49 enrolled

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 1·NCT03019991·18 enrolled

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01810887·8 enrolled

To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01813552·24 enrolled

Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02257008·44 enrolled

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RO6889678 and the Combination of RO6889678 With Ritonavir in Healthy Participants

Terminated· Roche logo

Roche·Phase 1·NCT02321384·100 enrolled

A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01392755·32 enrolled

HIV8 trials

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00028366·56 enrolled

A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients

Completed·AAbbott·N/A·NCT00002223

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

Completed·AAbbott·Phase 3·NCT00038636·36 enrolled

Show 5 more trials

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00531206·65 enrolled

A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients

Completed·AAbbott·N/A·NCT00002201

Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients

Completed·GGermans Trias i Pujol Hospital·Phase 4·NCT00355719·14 enrolled

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00528060·35 enrolled

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

Unknown status· GSK logo

GSK·Phase 3·NCT00025727·330 enrolled

71 more indications

Adult7 trials

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Completed·AAbbott·Phase 1·NCT00931281·38 enrolled

Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450

Completed·AAbbott·Phase 1·NCT01091649·40 enrolled

Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Completed·AAbbott·Phase 1·NCT00909311·8 enrolled

Show 4 more trials

Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253875·15 enrolled

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

Unknown status·KKirby Institute·Phase 4·NCT03017872·831 enrolled

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT05129475·12 enrolled

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

Completed· Roche logo

Roche·Phase 2·NCT00002239·68 enrolled

Drug6 trials

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

Unknown status· GSK logo

GSK·Phase 3·NCT00009061·624 enrolled

A Study to Compare Two Anti-HIV Drug Combinations

Completed· Roche logo

Roche·Phase 3·NCT00002447·146 enrolled

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000892·300 enrolled

Show 3 more trials

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002440·80 enrolled

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04055506·16 enrolled

A Study to Compare Two Different Anti-HIV Drug Regimens

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000924·120 enrolled

HIV infection6 trials

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT01232127·25 enrolled

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Completed·KKirby Institute·Phase 4·NCT00192660·80 enrolled

A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00006154·165 enrolled

Show 3 more trials

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT01691794·108 enrolled

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled

Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00006339

Efficacy and Safety6 trials

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Completed· Gilead logo

Gilead·Phase 1/2·NCT01565889·52 enrolled

Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00421551·225 enrolled

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 3·NCT03020082·141 enrolled

Show 3 more trials

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed·EEiger BioPharmaceuticals·Phase 3·NCT03719313·407 enrolled

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

Completed·HHarlan M Krumholz·Phase 2·NCT05668091·100 enrolled

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 2·NCT03020004·70 enrolled

Chronic Hepatitis5 trials

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Completed· Roche logo

Roche·Phase 2·NCT01278134·170 enrolled

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Completed· Roche logo

Roche·Phase 1·NCT01185860·59 enrolled

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

Completed·RR-Pharm·Phase 2·NCT03485846·105 enrolled

Show 2 more trials

A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00797745·111 enrolled

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 2/3·NCT03362814·425 enrolled

Children5 trials

Population Pharmacokinetics of Antiretroviral in Children

Completed·AAssistance Publique - Hôpitaux de Paris··NCT03194165·65 enrolled

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00919854·27 enrolled

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001083·240 enrolled

Show 2 more trials

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000952·60 enrolled

A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000913·50 enrolled

COVID-194 trials

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT05261139·160 enrolled

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT05047601·2,954 enrolled

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

Withdrawn· Pfizer logo

Pfizer·Phase 2·NCT05545319

Show 1 more trial

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

Completed· Pfizer logo

Pfizer·Phase 2·NCT05567952·436 enrolled

HIV-14 trials

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002374·120 enrolled

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

Completed· GSK logo

GSK·Phase 3·NCT00296504·753 enrolled

GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

Completed· GSK logo

GSK·Phase 2·NCT00257621·30 enrolled

Show 1 more trial

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002378·825 enrolled

Hepatic Impairment4 trials

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

Completed· Roche logo

Roche·Phase 1·NCT01185873·81 enrolled

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

Completed· Pfizer logo

Pfizer·Phase 1·NCT05005312·17 enrolled

A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls

Completed· Roche logo

Roche·Phase 1·NCT01714154·18 enrolled

Show 1 more trial

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

Completed·RR-Pharm·Phase 1·NCT03832426·32 enrolled

Hepatitis C4 trials

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Completed· AbbVie logo

AbbVie·Phase 2·NCT01464827·580 enrolled

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

Completed· AbbVie logo

AbbVie·Phase 1·NCT00850044·87 enrolled

Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients

Completed· Novartis logo

Novartis·Phase 1/2·NCT01825980·54 enrolled

Show 1 more trial

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01724086·90 enrolled

Immunodeficiency3 trials

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02275780·769 enrolled

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed· Gilead logo

Gilead·Phase 3·NCT01106586·708 enrolled

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

Completed· GSK logo

GSK·Phase 3·NCT01910402·499 enrolled

TED3 trials

Single and Repeated Dose Escalation Study of GSK2838232

Completed· GSK logo

GSK·Phase 1·NCT02795754·62 enrolled

A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01592318·42 enrolled

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Terminated· GSK logo

GSK·Phase 1·NCT02289495·24 enrolled

Drug Resistance3 trials

Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00120783·40 enrolled

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00046033·118 enrolled

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00027339·53 enrolled

Single Dose3 trials

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Terminated· GSK logo

GSK·Phase 1·NCT02289482·20 enrolled

Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253953·62 enrolled

Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253927·48 enrolled

Adult Subject3 trials

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·Phase 2·NCT00764465·45 enrolled

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·N/A·NCT00802074·45 enrolled

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·N/A·NCT00614991·44 enrolled

HIV-Infected Individuals3 trials

Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT02503462·7 enrolled

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000859·1,300 enrolled

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000822·46 enrolled

Immune System2 trials

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001119·288 enrolled

A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002448·40 enrolled

MPR2 trials

Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR

Completed· GSK logo

GSK·Phase 3·NCT00043888·60 enrolled

Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir

Completed·RRadboud University Medical Center·Phase 1·NCT00817765·24 enrolled

Kaposi's sarcoma2 trials

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003008·33 enrolled

The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma

Completed·AAbbott·Phase 2·NCT00002366

Pediatric2 trials

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

Completed· GSK logo

GSK·Phase 2·NCT00071760·59 enrolled

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

Completed· GSK logo

GSK·Phase 2·NCT00040664·69 enrolled

Pregnant Women2 trials

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00855335·77 enrolled

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000888·14 enrolled

ART2 trials

Comparative Study of Three NNRTI-Sparing HAART Regimens

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT00811954·1,814 enrolled

Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants

Unknown status·FFujian Akeylink Biotechnology Co., Ltd.·Phase 1·NCT06084507·18 enrolled

Tenofovir Disoproxil Fumarate2 trials

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT00118898·1,864 enrolled

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

Completed· Roche logo

Roche·Phase 1·NCT01592305·40 enrolled

HIV-1 infection2 trials

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Approved for marketing· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00097799

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00976950·42 enrolled

Drug Interactions2 trials

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00005762·90 enrolled

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00833482·185 enrolled

Hepatitis2 trials

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT02511431·22 enrolled

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT03600714·26 enrolled

MPA2 trials

Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02259868·88 enrolled

Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02183441·12 enrolled

Randomized2 trials

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00440271·33 enrolled

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Completed· AbbVie logo

AbbVie·Phase 2·NCT01074008·74 enrolled

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00447902·11 enrolled

Pregnancy1 trial

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000920·24 enrolled

Pilot Study1 trial

A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001688·25 enrolled

Advanced Breast Cancer1 trial

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT06710990·32 enrolled

Second-line Treatment1 trial

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01605084

Antiretroviral Treatment1 trial

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

Withdrawn·JJuan A. Arnaiz·Phase 4·NCT02470650

Phase II1 trial

Phase IIB Pilot of Atazanavir + Raltegravir

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00768989·167 enrolled

Radiation Therapy1 trial

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

Unknown status·OOncology Institute of Southern Switzerland·Phase 2·NCT00637637·60 enrolled

Drug Therapy1 trial

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000902·217 enrolled

Viremia1 trial

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT00855413·15 enrolled

Pediatric Patients1 trial

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01335698·160 enrolled

Imaging1 trial

LAAM-HAART PET Imaging

Completed·WWashington University School of Medicine·Phase 1·NCT01935830·10 enrolled

Toxicity1 trial

NNRTI/PI Toxicity Switch to Darunavir Study

Terminated·SSt Stephens Aids Trust·Phase 4·NCT00765154·12 enrolled

Menstrual Cycle1 trial

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT00869960·24 enrolled

Impaired Renal Function1 trial

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT02116660·11 enrolled

Combination Therapy1 trial

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01448707·274 enrolled

Hepatitis D Virus Infection1 trial

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection

Unknown status·SSoroka University Medical Center·Phase 3·NCT05229991·30 enrolled

Mycobacterium Avium Complex1 trial

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001058·246 enrolled

Adolescent1 trial

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00006604·195 enrolled

CLE1 trial

Nucleosides And Darunavir/Dolutegravir In Africa

Unknown status·MMakerere University·Phase 3·NCT03988452·465 enrolled

Tuberculosis1 trial

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT04518228·205 enrolled

Platelet Function1 trial

Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02251795·52 enrolled

Immune Response1 trial

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006578

Glioblastoma1 trial

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Completed·UUniversity of Ulm·Phase 1/2·NCT02770378·10 enrolled

Statin1 trial

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

Completed·NNYU Langone Health·Phase 1·NCT01695954·34 enrolled

Tenofovir1 trial

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Completed·UUniversity of North Carolina, Chapel Hill··NCT01180075·85 enrolled

Advanced1 trial

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000891·34 enrolled

Female1 trial

Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253888·30 enrolled

Atorvastatin1 trial

Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02245269·23 enrolled

Breast Cancer1 trial

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT01009437·28 enrolled

Treatment Failure1 trial

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000918·300 enrolled

Progesterone1 trial

Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00016601·76 enrolled

Maintenance Therapy1 trial

Atazanavir/Ritonavir Maintenance Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00084019·36 enrolled

Amyotrophic Lateral Sclerosis1 trial

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT02437110·122 enrolled

Bone1 trial

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01400412·262 enrolled

Cardiovascular1 trial

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections··NCT00851799·334 enrolled

Function1 trial

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

Completed· GSK logo

GSK·Phase 4·NCT00717067·30 enrolled

Inflammation1 trial

Inflammation and Co-Infections in D²EFT

Withdrawn·KKirby Institute·Phase 4·NCT04183738

Women1 trial

Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs

Unknown status·PPPD Development, LP·Phase 3·NCT00006397·200 enrolled

Observational Study1 trial

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT01615601·77 enrolled

Unspecified6 trials

A Study of Lonafarnib With or Without Ritonavir in Patients With HDV

Withdrawn·EEiger BioPharmaceuticals·Phase 2·NCT02968641

A Study of RO5190591 (Danoprevir) in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01164488·18 enrolled

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

Completed· GSK logo

GSK·Phase 3·NCT00085943·866 enrolled

Show 3 more trials

Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253862·17 enrolled

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

Completed·—·Phase 4·NCT00677300·85 enrolled

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

Completed·PPyramid Biosciences·Phase 1·NCT05692570·21 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 1, 1996

NORVIR

NDA NDA020659

Mar 1, 1996

NORVIR

NDA NDA020680

Jun 29, 1999

NORVIR

NDA NDA020945

Feb 10, 2010

NORVIR

NDA NDA022417

Apr 27, 2010

NORVIR

NDA NDA022417

Dec 6, 2011

NORVIR

NDA NDA022417

Feb 17, 2012

NORVIR

NDA NDA022417

Nov 20, 2012

NORVIR

NDA NDA022417

Nov 7, 2013

NORVIR

NDA NDA022417

Mar 16, 2015

NORVIR

NDA NDA022417

Mar 27, 2015

NORVIR

NDA NDA022417

Nov 10, 2015

NORVIR

NDA NDA022417

Sep 15, 2016

NORVIR

NDA NDA022417

Nov 22, 2016

NORVIR

NDA NDA022417

Dec 22, 2016

NORVIR

NDA NDA022417

Jun 7, 2017

NORVIR

NDA NDA022417

Jun 7, 2017

NORVIR

NDA NDA209512

Jun 29, 2017

NORVIR

NDA NDA022417

Jun 29, 2017

NORVIR

NDA NDA209512

Sep 29, 2017

NORVIR

NDA NDA209512

Sep 29, 2017

NORVIR

NDA NDA022417

Nov 15, 2018

NORVIR

NDA NDA022417

Nov 15, 2018

NORVIR

NDA NDA209512

Aug 21, 2019

NORVIR

NDA NDA022417

Aug 21, 2019

NORVIR

NDA NDA209512

Dec 19, 2019

NORVIR

NDA NDA209512

Dec 19, 2019

NORVIR

NDA NDA022417

Oct 21, 2020

NORVIR

NDA NDA209512

Oct 21, 2020

NORVIR

NDA NDA022417

Dec 15, 2022

NORVIR

NDA NDA022417

Dec 15, 2022

NORVIR

NDA NDA209512

Jul 23, 2026

NORVIR

NDA NDA209512

Jul 23, 2026

NORVIR

NDA NDA022417

Sources

References

[1]
ClinicalTrials.gov — 319 trial records for Ritonavir. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Norvir drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ritonavir compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ritonavir. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA209512). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cytochrome P450 3a Inhibitor; Human Immunodeficiency Virus Type 1 Protease Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AbbVie

Norvir

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Interaction17 trials

Effectiveness12 trials

Treatment11 trials

Tics11 trials

HIV8 trials

Adult7 trials

Drug6 trials

HIV infection6 trials

Efficacy and Safety6 trials

Chronic Hepatitis5 trials

Children5 trials

COVID-194 trials

HIV-14 trials

Hepatic Impairment4 trials

Hepatitis C4 trials

Immunodeficiency3 trials

TED3 trials

Drug Resistance3 trials

Single Dose3 trials

Adult Subject3 trials

HIV-Infected Individuals3 trials

Immune System2 trials

MPR2 trials

Kaposi's sarcoma2 trials

Pediatric2 trials

Pregnant Women2 trials

ART2 trials

Tenofovir Disoproxil Fumarate2 trials

HIV-1 infection2 trials

Drug Interactions2 trials

Hepatitis2 trials

MPA2 trials

Randomized2 trials

Drug Monitoring1 trial

Tolerance1 trial

HBV1 trial

Pregnancy1 trial

Pilot Study1 trial

Advanced Breast Cancer1 trial

Second-line Treatment1 trial

Antiretroviral Treatment1 trial

Phase II1 trial

Radiation Therapy1 trial

Drug Therapy1 trial

Viremia1 trial

Pediatric Patients1 trial

Imaging1 trial

Toxicity1 trial

Menstrual Cycle1 trial

Impaired Renal Function1 trial

Combination Therapy1 trial

Hepatitis D Virus Infection1 trial

Mycobacterium Avium Complex1 trial

Adolescent1 trial

CLE1 trial

Tuberculosis1 trial

Platelet Function1 trial

Immune Response1 trial

Glioblastoma1 trial

Statin1 trial

Tenofovir1 trial

Advanced1 trial

Female1 trial

Atorvastatin1 trial

Breast Cancer1 trial

Treatment Failure1 trial

Progesterone1 trial

Maintenance Therapy1 trial

Amyotrophic Lateral Sclerosis1 trial

Bone1 trial

Cardiovascular1 trial

Function1 trial

Inflammation1 trial

Women1 trial

Observational Study1 trial

Unspecified6 trials